242 related articles for article (PubMed ID: 15566356)
21. Regulatory effects of IL-4 on human B-cell response to IL-2.
Galanaud P; Karray S; Llorente L
Eur Cytokine Netw; 1990; 1(2):57-64. PubMed ID: 2102812
[TBL] [Abstract][Full Text] [Related]
22. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
[TBL] [Abstract][Full Text] [Related]
23. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
24. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.
McWhirter JR; Kretz-Rommel A; Saven A; Maruyama T; Potter KN; Mockridge CI; Ravey EP; Qin F; Bowdish KS
Proc Natl Acad Sci U S A; 2006 Jan; 103(4):1041-6. PubMed ID: 16418292
[TBL] [Abstract][Full Text] [Related]
25. Expression of IL-4 receptor on human T and B lymphocytes.
Zola H; Flego L; Weedon H
Cell Immunol; 1993 Aug; 150(1):149-58. PubMed ID: 7688267
[TBL] [Abstract][Full Text] [Related]
26. Exogenous interleukin 2 (IL 2) reconstitutes deficient in vitro T-cell growth of patients with chronic lymphocytic leukemia of B-cell lineage (B-CLL).
Jehn U; Gross HJ; Wachholz K; Pauls R
Anticancer Res; 1990; 10(4):929-34. PubMed ID: 2382990
[TBL] [Abstract][Full Text] [Related]
27. Activation antigens on colonic T cells in inflammatory bowel disease: effects of IL-10.
Ebert EC; Mehta V; Das KM
Clin Exp Immunol; 2005 Apr; 140(1):157-65. PubMed ID: 15762887
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-2, but not interleukin-15, is required to terminate experimentally induced clonal T-cell anergy.
Bendiksen S; Rekvig OP
Scand J Immunol; 2004; 60(1-2):64-73. PubMed ID: 15238074
[TBL] [Abstract][Full Text] [Related]
29. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
30. B cells play a regulatory role in mice infected with the L3 of Brugia pahangi.
Gillan V; Lawrence RA; Devaney E
Int Immunol; 2005 Apr; 17(4):373-82. PubMed ID: 15724063
[TBL] [Abstract][Full Text] [Related]
31. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells.
Kato K; Chu P; Takahashi S; Hamada H; Kipps TJ
Exp Hematol; 2007 Mar; 35(3):434-42. PubMed ID: 17309824
[TBL] [Abstract][Full Text] [Related]
32. Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia.
Colovai AI; Tsao L; Wang S; Lin H; Wang C; Seki T; Fisher JG; Menes M; Bhagat G; Alobeid B; Suciu-Foca N
Cytometry B Clin Cytom; 2007 Sep; 72(5):354-62. PubMed ID: 17266150
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells.
Spaner DE; Shi Y; White D; Mena J; Hammond C; Tomic J; He L; Tomai MA; Miller RL; Booth J; Radvanyi L
Leukemia; 2006 Feb; 20(2):286-95. PubMed ID: 16341037
[TBL] [Abstract][Full Text] [Related]
34. Early immune response and regulation of IL-2 receptor subunits.
Hughes-Fulford M; Sugano E; Schopper T; Li CF; Boonyaratanakornkit JB; Cogoli A
Cell Signal; 2005 Sep; 17(9):1111-24. PubMed ID: 15993752
[TBL] [Abstract][Full Text] [Related]
35. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells.
Muzio M; Scielzo C; Bertilaccio MT; Frenquelli M; Ghia P; Caligaris-Cappio F
Br J Haematol; 2009 Feb; 144(4):507-16. PubMed ID: 19036098
[TBL] [Abstract][Full Text] [Related]
36. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Corallini F; Barbarotto E; Melloni E; di Iasio MG; Tiribelli M; Zauli G
J Cell Physiol; 2006 Apr; 207(1):158-64. PubMed ID: 16270354
[TBL] [Abstract][Full Text] [Related]
37. Requirement of 8-mercaptoguanosine as a costimulus for IL-4-dependent mu to gamma1 class switch recombination in CD38-activated B cells.
Tsukamoto Y; Uehara S; Mizoguchi C; Sato A; Horikawa K; Takatsu K
Biochem Biophys Res Commun; 2005 Oct; 336(2):625-33. PubMed ID: 16143305
[TBL] [Abstract][Full Text] [Related]
38. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
[TBL] [Abstract][Full Text] [Related]
39. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
Decker T; Schneller F; Kronschnabl M; Dechow T; Lipford GB; Wagner H; Peschel C
Exp Hematol; 2000 May; 28(5):558-68. PubMed ID: 10812246
[TBL] [Abstract][Full Text] [Related]
40. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.
Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH
Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
